{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Will employ Kaplan-Meier and Cox proportional hazard model methodology.","groups":[{"description":"Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nNivolumab: Given IV","id":"OG000","title":"Treatment (Nivolumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From first study drug administration to the first occurrence of disease progression or death from any cause, up to 1 year and 8 months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Participants"}